Aviva G. Asnis-Alibozek, DMSc, PA-C, DFAAPA
The purpose of this article is to review the significance of vitiligo in the dermatology office, explore its classification method, and discuss the current and upcoming therapeutic options. Evidence collation was obtained through PubMed key word searches yielding meta-analyses, systematic reviews, and randomized control trials primarily within the last five years, except when reviewing for historical context.
Vitiligo is a variable disorder of skin depigmentation where destruction of melanocytes results in well-demarcated leukoderma. Etiology is thought to be immune mediated in most situations, though exact mechanisms are unknown. There is no cure available currently. The only FDA-approved therapy, monobenzone, targets normal skin for depigmentation as opposed to treating diseased skin, thus many off-label therapies are routinely utilized. Common treatment modalities include topical corticosteroids, vitamin-D analogs, calcineurin inhibitors, phototherapy, laser therapy, and surgery. Investigational therapies include afamelanotide implants and Janus kinase inhibitors.
Stevens GM. Vitiligo: A Clinical Review. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.